2 reports of this reaction
2.2% of all GUAIFENESIN AND PSEUDOEPHEDRINE HCL reports
#2 most reported adverse reaction
INFUSION SITE ERYTHEMA is the #2 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, manufactured by H E B. There are 2 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HCL to INFUSION SITE ERYTHEMA. This represents approximately 2.2% of all 92 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HCL who experience infusion site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE ERYTHEMA is a less commonly reported adverse event for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, but still significant enough to appear in the safety profile.
In addition to infusion site erythema, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HCL:
The following drugs have also been linked to infusion site erythema in FDA adverse event reports:
INFUSION SITE ERYTHEMA has been reported as an adverse event in 2 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE ERYTHEMA accounts for approximately 2.2% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, making it one of the most commonly reported side effect.
If you experience infusion site erythema while taking GUAIFENESIN AND PSEUDOEPHEDRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.